The Use of I.V. Albumin During Kidney Replacement Therapy: A Survey of Nephrologists and Intensivists

• Ryan J. Chan,
• William Beaubien-Souligny,
• Samuel A. Silver,
• Sean M. Bagshaw,
• Ron Wald,
• Pierre-Antoine Brown,
• Swapnil Hiremath,
• Jennifer W.Y. Kong,
• Edward G. Clark

Affiliations

Ryan J. Chan

Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

William Beaubien-Souligny

Division of Nephrology, Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada

Samuel A. Silver

Division of Nephrology, Department of Medicine, Queen’s University, Kingston, Ontario, Canada

Sean M. Bagshaw

Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

Ron Wald

Division of Nephrology, St. Michael’s Hospital (Unity Health), University of Toronto, Toronto, Ontario, Canada

Pierre-Antoine Brown

Division of Nephrology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada; Kidney Research Centre and Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Swapnil Hiremath

Division of Nephrology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada; Kidney Research Centre and Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Jennifer W.Y. Kong

Kidney Research Centre and Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Edward G. Clark

Division of Nephrology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada; Kidney Research Centre and Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Correspondence: Edward G. Clark, Division of Nephrology, Department of Medicine, The Ottawa Hospital—Riverside Campus, 1967 Riverside Drive, Ottawa, Ontario K1H 7W9, Canada.